Gene editing was supposed to be clean. The patent fight wasnt.
For fourteen years, CRISPR has moved from a breakthrough scientific idea to a platform technology that promises cures, not just therapies. Investors backed the platform. Patients waited f…
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Drug patenting has long been treated like the scoreboard of pharmaceutical strategy. If a patent expires, everyone watches the clock. If a court decision lands, the market reacts. But the re…
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
If youve ever searched Google Patents for a drug name and thought, Greatthis will show me everything that matters, youre not alone.
But heres the problem: Google Patents wasnt built for pharma workflows. It was built for broad, general-purpose discover…
A Three-Week Analyst Report That Shouldve Been Three Hours: Heres the Bottleneckand How to Fix It
In most industries, time is the cheapestand most underpricedasset you can manage.
So when a seemingly straightforward deliverable stretches from three hou…
ð¨ Your competitive intelligence team isnt behind. Its leaking timeevery day.
If your workflow still looks like:
log into PACER
search case by case
download PDFs
manually dedupe matters
forward updates to stakeholders
then youre not jus…
Generic drug launches are the infuriating cliffhanger pharma loves to debate and regulators desperately try to forecast: the patent expires, the calendar flips, and yetno generic. Or maybe it arrives later than expected. If youve worked around branded-…
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates Read Post »
The Patent Cliff Is Mostly a MythWhat Actually Happens Is a Patent Staircase (and Most Models Miss the Steps)
If youve ever sat in a forecast meeting where a single date was treated like a finish linepatent cliff here, revenue collapse therethis post i…
Strong IP doesnt always win in courtheres what does.
In pharma, weve built a comforting story: the patents are strong, the claims are clear, and the courtroom will simply recognize whats right. But recent enforcement trends suggest something tougherand…
Strong IP Doesn’t Win in Court. Enforceable IP Does. Read Post »
Most people think loss of exclusivity is the story. It isnt. The story is pricing power.
For years, the industrys shorthand has been: patents expire, exclusivity ends, generics flood the market, revenue falls. Its a clean narrativeand a convenient one….
Legal firepower gets headlines. But in drug patent litigation, the real differentiator is often quieter: prior art search quality.
The agitation: too many teams treat prior art the way they treat discoverysomething you collect after the case is filed, …
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation Read Post »